Rheumatoid arthritis (RA) is a chronic inflammatory autoimmune disease that typically affects the hands and feet, although any joint lined by a synovial membrane may be affected. Now Pfizer has announced progress for their drug tofacitinib. Tofacitinib is a unique, oral Janus kinase (JAK) inhibitor that is being investigated as a targeted immunomodulator and disease-modifying therapy for RA. More than 4,000 RA patients have been treated with tofacitinib in clinical trials to date. RA affects approximately 1.3 million people in the U.S. and one percent of the adult population worldwide...
No comments:
Post a Comment